

ZELSUVMI™, a first-in-class topical medication, is now FDA approved as the first novel drug* for the treatment of molluscum contagiosum.
ZELSUVMI™ Gel is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.
Available Summer 2025
Important Safety Information:
Warnings: Application site reactions, including, allergic contact dermatitis occurred. Discontinue ZELSUVMI and initiate appropriate therapy.
Adverse Reactions: The most commonly reported adverse reactions (≥1%) are application site reactions including pain (such as burning or stinging sensations, 18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
*Novel Drug Approvals for 2024 | FDA
©2025 LNHC, Inc. All Rights Reserved
Privacy Policy
Terms of Use


ZELSUVMI™, a first-in-class topical medication, is now FDA approved as the first novel drug* for the treatment of molluscum contagiosum.
ZELSUVMI™ Gel is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.

Important Safety Information:
Warnings: Application site reactions, including, allergic contact dermatitis occurred. Discontinue ZELSUVMI and initiate appropriate therapy.
Adverse Reactions: The most commonly reported adverse reactions (≥1%) are application site reactions including pain (such as burning or stinging sensations, 18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
*Novel Drug Approvals for 2024 | FDA
©2025 LNHC, Inc. All Rights Reserved
Privacy Policy
Terms of Use